Levetiracetam
Product Images NDC 71093-144

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 71093-144). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aci Healthcare Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-01 (Image 01)

Chemical structure diagram of levetiracetam showing its molecular framework, including a pyrrolidone ring and attached functional groups: an ethyl group, an amide group, and a chiral center.*

FDA Label Image

Image-02 (Levetiracetam Fig1)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' showing the percentage of patients responding to treatments. It compares placebo with Levetiracetam 1000 mg/day and 3000 mg/day, indicating 7.4%, 37.1%, and 39.6% responder rates respectively. The chart notes statistical significance versus placebo for Levetiracetam groups.*

FDA Label Image

Image-01 (Levetiracetam Fig2)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing the percentage of patients responding across three groups: placebo, levetiracetam 1000 mg/day, and levetiracetam 2000 mg/day. The responder rates are 6.3%, 20.8%, and 35.2% respectively, with both levetiracetam doses marked as statistically significant versus placebo.*

FDA Label Image

Image-03 (Levetiracetam Fig3)

A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' showing percentage of patients responding. One bar represents placebo (N=104) with a responder rate of 14.4%. The other bar represents Levetiracetam 3000 mg/day (N=180) with a responder rate of 39.4%, marked as statistically significant versus placebo.*

FDA Label Image

Image-04 (Levetiracetam Fig4)

Bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing the percentage of patients responding to Placebo and Levetiracetam. The chart shows 19.6% responder rate for Placebo (N=97) and 44.6% for Levetiracetam (N=101), with a note indicating statistical significance versus placebo.*

FDA Label Image

Image-05 (Levetiracetam Fig5)

Bar graph titled 'Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5' showing percentage of patients responding to Placebo (19.6%, N=51) versus Levetiracetam (43.1%, N=58). The Levetiracetam response rate is marked as statistically significant compared to placebo.*

FDA Label Image

Image-06 (Levetiracetam Fig6)

Bar graph showing responder rates (≥50% reduction from baseline) in PGTC seizure frequency per week in Study 7. The graph compares placebo (45.2% of 84 patients) with Levetiracetam (72.2% of 79 patients), indicating a statistically significant improvement with Levetiracetam versus placebo.*

FDA Label Image

Image-8 (Levetiracetam Label)

Levetiracetam Oral Solution, USP 100 mg/mL in a 473 mL bottle. The label features a green and brown color block design and includes dosage information stating each 1 mL contains 100 mg levetiracetam USP. It is manufactured by ACI Healthcare USA, Inc. and displays the product NDC 71093-144-13 along with directions to keep out of reach of children and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.